| Krypton Street Announces Galmed Pharmaceuticals (Nasdaq: GLMD) As Its Next Potential Breakout Idea For Tomorrow.
Here’s What We Can Tell You—So Far…
Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of Over 597% From Its $1.72 Close.
There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift.
According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal.
Take A Quick Look At Galmed Pharmaceuticals (NASDAQ: GLMD) Tonight—We Will Have All Eyes On This One Monday Morning.
March 16, 2025
Dear Reader,
We’re bringing Galmed Pharmaceuticals (Nasdaq: GLMD) back into focus as our next potential breakout idea for Monday, 3/17/2025.
If you’ve been following us for a while, you’ll know that the last time we highlighted (GLMD), it moved approximately 182% in under 24 hours.
Given that our last two Sunday Night Profiles showcased a combined 175% (approx.) in moves, we have every reason to believe that (GLMD) could be one to watch closely tomorrow morning.
You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight.
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.
The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.
Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.
As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here.
On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close.
Here’s 3 Reasons Why Galmed Pharmaceuticals (Nasdaq: GLMD) Is Topping Our Watchlist Tomorrow Morning…
1. Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close.
2. Ultra Low Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift.
3. Technical Indicators: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal.
Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD) to Your Radar Tomorrow…
When a profile like this starts catching momentum, things can move fast—we’ve seen it happen before.
Consider taking a look at (GLMD) tonight before you go to sleep.
(GLMD) will be at the top of our screens early tomorrow morning.
And don’t forget— the last time we covered (GLMD), it moved approximately 182% in less than 24 hours.
Please keep an eye out for my morning update. | 
ليست هناك تعليقات:
إرسال تعليق